Remed

REMED operates at the intersection of medical-device manufacturing, health care, and neurostimulation. Its stated product scope covers electromagnetic stimulation, RSWT, and laser therapy, while its website information adds Transcranial Magnetic Stimulation (TMS), Neuromuscular Magnetic Stimulation (NMS), and Core Strength Magnetic Stimulation (CSMS). This breadth gives the company a modality-led profile across neurological treatment, pain management, and aesthetic applications rather than a position centered on a single device type. The listed similarity entries resolve to REMED itself and therefore are not suitable competitors. Differentiation can be described only at the portfolio level: REMED combines magnetic stimulation with shockwave and laser-based therapies and develops devices as well as core components.

REMED was founded in 2003 and has developed a portfolio spanning electromagnetic stimulation, RSWT, and laser therapy devices. The long interval between that recorded financing and the present provides no basis for inferring either further fundraising or the company’s financial trajectory. Product information points to continued technical breadth, including TMS, NMS, CSMS, focused shock wave therapy, and a brain-navigation-enabled stimulation device. The company also has nine granted patents. Overall, the evidence supports a long-operating medical-device manufacturer with multiple therapeutic modalities and international commercial activity, but it is insufficient to assess whether growth is accelerating, stable, or contracting.